ANTI-alphaVbeta8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE

Provided are methods and compositions for treating kidney disease, such as chronic kidney disease (CKD), in which the methods and compositions comprise antibodies or an antigen binding fragment thereof that specifically and selectively bind to human αvβ8 integrin, which was discovered, as described,...

Full description

Saved in:
Bibliographic Details
Main Authors LIARTE MARIN, Elena, MORENO-QUINN, Carol, Patricia, HERRERA, Maria, Marcela, MURRAY, Lynne, Anne, HEASMAN, Stephanie, Claire, BAKER, David, James, WU, Yanli, TSUI, Ping
Format Patent
LanguageEnglish
French
German
Published 07.12.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided are methods and compositions for treating kidney disease, such as chronic kidney disease (CKD), in which the methods and compositions comprise antibodies or an antigen binding fragment thereof that specifically and selectively bind to human αvβ8 integrin, which was discovered, as described, to be highly expressed on kidney cells and tissue, and, in particular, diseased or fibrotic kidney tissue. The disclosed anti-αvβ8 integrin antibodies bind to human αvβ8 integrin in the kidney and block the activation of TGF-β from its latent form in kidney tissue. The anti-αvβ8 antibodies in the disclosed methods reduce, attenuate, or abrogate kidney fibrosis, which is associated with the activities of αvβ8 integrin and TGF-β in kidney tissue. The disclosed antibodies and methods effectively treat kidney disease, in particular, fibrosis associated with kidney disease, such as CKD, in individuals in need thereof.
Bibliography:Application Number: EP20210703839